Stock Market Watch

Gilead Obtaining Approval for HIV Drug

by ·

Gilead Sciences (NASDAQ:GILD) has asked the Food and Drug administration to approve its HIV treatment drug for AIDS. The single pill treatment for AIDS is a combination of the two proprietary drugs Tibotec and Rilpivirine. These drugs are manufactured in partnership with Tibotec.

The drugs have been in development since July 2009 and are at the preclinical stage.  Gilead Sciences (NASDAQ:GILD) already owns and sells the other HIV drug which is a combination of three drugs. Truvada and Atripla are a big part of this drug. Johnson & Johnson (NYSE:JNJ) owns Tibotec, which sells Rilpivirine as a cure for HIV.

Related posts:

  1. J&J Recalling Benadryl and Motrin
  2. Finding The Source of HIV
  3. Bird Flu Resurfaces
  4. Japanese Firm buying Genzyme
  5. GE, T, GILD, BMY, MF are Stocks Trending Up



Tags:

Ed Liston

Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing.

You may also like...